Serotonin 1D (5-HT1D) agonists and other agents in acute migraine.
This article discusses the use of serotonin1D agonists in the treatment of acute migraine. Specifically, the author reviews the efficacy and safety of this class of drugs with sumatriptan as the main focus. Agents under clinical trial are also discussed. Recurrence of migraine, long-term usage, and side effects of serotonin1D agonists are included in the review. The article also discusses alternative medications, such as intranasal lidocraine, intravenous chlorpromazine, and intravenous prochlorperazine, for acute treatment of migraine. The limited role of narcotics and sedatives is also mentioned.
Mathew
N T
NT
Houston Headache Clinic, Texas, USA.
D000208:Acute Disease; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D003027:Cluster Headache / Q000188:drug therapy; D004087:Dihydroergotamine / Q000627:therapeutic use; D004347:Drug Interactions; D006801:Humans; D008881:Migraine Disorders / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D012008:Recurrence; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D018170:Sumatriptan / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
D018712:Analgesics, Non-Narcotic; D017366:Serotonin Receptor Agonists; D014662:Vasoconstrictor Agents; D004087:Dihydroergotamine; D018170:Sumatriptan